Aug 17, 2023 / 04:00PM GMT
John Newton Sourbeer - UBS Investment Bank, Research Division - Equity Research Associate
Hi I'm John Sourbeer, one of the Life Sciences analyst here at UBS. Final day of the 2023 UBS Life Sciences Conference here (inaudible) the Life Science portion here with a fireside chat with Illumina. Joining us today is Sally Schwartz, VP of Investor Relations. Sally, thanks for joining us.
Sallilyn Schwartz - Illumina, Inc. - VP of IR
Thank you for having me.
John Newton Sourbeer - UBS Investment Bank, Research Division - Equity Research Associate
So you guys recently reported 2Q earnings last week, but maybe just start off with a recap in the lower guidance. There's certainly been larger macro issues throughout the life sciences industry, but maybe some of the puts and takes on China slower-than-expected NovaSeq X ramp and some of the general budget pressures across customers.
Sallilyn Schwartz - Illumina, Inc. - VP of IR
Sure. And maybe just as a quick recap. We previously had
Illumina Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers